347396-82-1
347396-82-1 structure
- Name: Ranibizumab (anti-VEGF)
- Chemical Name: Ranibizumab
- CAS Number: 347396-82-1
- Molecular Formula: C2158H3282N562O681S12
- Molecular Weight:
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK VEGFR
- Create Date: 2018-03-31 08:00:00
- Modify Date: 2025-09-12 16:47:05
-
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1].
| Name | Ranibizumab |
|---|---|
| Synonyms | Lucentis |
| Description | Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317)[2]. Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures[3]. |
| In Vivo | Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24 h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1 h after intravitreal administration in rabbits[1]. In a study comparing the pharmacokinetics of 0.5 mg of intravitreal Ranibizumab with 1.25 mg of intravitreal Bevacizumab in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7 μg/ml for Bevacizumab and 17.9 μg/ml for Ranibizumab, respectively[1]. |
| Molecular Formula | C2158H3282N562O681S12 |
|---|